✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Mipsagargin is an investigational drug.
There have been 6 clinical trials for Mipsagargin. The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2014.
The most common disease conditions in clinical trials are Glioblastoma, Carcinoma, and Carcinoma, Hepatocellular. The leading clinical trial sponsors are GenSpera, Inc., John Wayne Cancer Institute, and [disabled in preview].
There are three US patents protecting this investigational drug and nine international patents.
Recent Clinical Trials for Mipsagargin
|Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma||John Wayne Cancer Institute||Phase 2|
|Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma||GenSpera, Inc.||Phase 2|
|Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA||GenSpera, Inc.||Phase 2|
Top disease conditions for Mipsagargin
Top clinical trial sponsors for Mipsagargin
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Mipsagargin||See Plans and Pricing||Methods of treating glioblastoma multiforme using ibudilast||MediciNova, Inc. (La Jolla, CA)||See Plans and Pricing|
|Mipsagargin||See Plans and Pricing||Methods of treating disorders with glycosylation defective proteins||CASE WESTERN RESERVE UNIVERSITY (Cleveland, OH)||See Plans and Pricing|
|Mipsagargin||See Plans and Pricing||Methods and dosing regimens using ibudilast and a second agent for cancer therapy||MediciNova, Inc. (La Jolla, CA)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Mipsagargin||European Patent Office||EP3558301||2036-12-22||See Plans and Pricing|
|Mipsagargin||Japan||JP2020504721||2036-12-22||See Plans and Pricing|
|Mipsagargin||World Intellectual Property Organization (WIPO)||WO2018119262||2036-12-22||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|